Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Niklas Bergvall
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
Advances in Therapy
Medicine
Pharmacology
Related publications
Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis
Neuropsychiatric Disease and Treatment
Psychiatry
Mental Health
Biological Psychiatry
Cerebrovascular Reactivity and Disease Activity in Relapsing-Remitting Multiple Sclerosis
Advances in Clinical and Experimental Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Chemical Health
Pharmacology
Safety
Medicine
Toxicology
Safety Research
Pharmaceutics
Oral Therapies for Treatment of Relapsing–remitting Multiple Sclerosis in Austria: A 2-Year Comparison Using an Inverse Probability Weighting Method
Journal of Neurology
Neurology
Permeability of the Blood-Brain Barrier Predicts No Evidence of Disease Activity at Two Years After Natalizumab or Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis
Annals of Neurology
Neurology
Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Archives of Neurology
Correction To: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis
CNS Drugs
Psychiatry
Mental Health
Neurology
Pharmacology
Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
Journal of Managed Care Pharmacy
